Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy

Journal of Urology

Volumn 184, Issue 3, 2010, Pages 925-929

  Tollefson, Matthew K ^a   Blute, Michael L ^a   Rangel, Laureano J ^a   Karnes, R Jeffrey ^a   Frank, Igor ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; BLOOD; HEALTH SURVEY; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 77956635392     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.05.043     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. L.C. Harlan, A. Potosky, and F.D. Gilliland Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study J Natl Cancer Inst 93 2001 1864
3. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 19752006. Bethesda: National Cancer Institute. Based on November 2008 SEER data submission posted to the SEER web site 2009. Available at http://seer.cancer. gov/csr/1975-2006/.
4. M.L. Blute, E.J. Bergstralh, and A. Iocca Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy J Urol 165 2001 119
5. M. Graefen, P.I. Karakiewicz, and I. Cagiannos Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer J Clin Oncol 20 2002 951
6. M. Graefen, P.I. Karakiewicz, and I. Cagiannos International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy J Clin Oncol 20 2002 3206
7. K.L. Greene, M.V. Meng, and E.P. Elkin Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) J Urol 171 2004 2255
8. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499
9. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005
10. W. Dale, J. Hemmerich, and K. Bylow Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study J Clin Oncol 27 2009 1557
11. K. Chism, and E.J. Kunkel Prostate cancer: issues in psychosomatic medicine Curr Psychiatry Rep 11 2009 205
12. R.P. Myers The surgical management of prostate cancer: radical retropubic and radical perineal prostatectomy H. Lepor, Prostatic Diseases 1999 W.B. Saunders Co Philadelphia chapt 33
13. S.A. Boorjian, R.J. Karnes, and P.L. Crispen The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy J Urol 181 2009 95
14. S. Woloshin, L.M. Schwartz, and H.G. Welch The risk of death by age, sex, and smoking status in the United States: putting health risks in context J Natl Cancer Inst 100 2008 845
15. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
16. J.F. Ward, M.L. Blute, and J. Slezak The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 2003 1872
17. T.J. Sebo, J.C. Cheville, and D.L. Riehle Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer Am J Surg Pathol 26 2002 431
18. N.E. Hoffmann, Y. Sheinin, and C.M. Lohse External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma Cancer 112 2008 1471
19. G. Chavin, Y. Sheinin, and P.L. Crispen Expression of immunosuppressive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases Clin Cancer Res 15 2009 2174
20. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
21. M.W. Kattan, J.A. Eastham, and T.M. Wheeler Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors J Urol 170 2003 1792
22. P.J. Bastian, L.A. Mangold, and J.I. Epstein Characteristics of insignificant clinical T1c prostate tumors A contemporary analysis Cancer 101 2004 2001
23. F.K. Chun, A. Haese, and S.A. Ahyai Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men Cancer 113 2008 701
24. C.L. Amling, M.L. Blute, and E.J. Bergstralh Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years J Urol 164 2000 101
25. M.K. Tollefson, J.M. Slezak, and B.C. Leibovich Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy Mayo Clin Proc 82 2007 422